StockNews.com assumed coverage on shares of VBI Vaccines (NASDAQ:VBIV – Free Report) in a report published on Saturday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
VBI Vaccines Stock Performance
VBI Vaccines stock opened at $0.71 on Friday. The stock’s 50-day moving average is $0.61 and its 200-day moving average is $0.62. VBI Vaccines has a 12 month low of $0.45 and a 12 month high of $2.90.
VBI Vaccines (NASDAQ:VBIV – Get Free Report) last issued its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.02). VBI Vaccines had a negative net margin of 881.79% and a negative return on equity of 525.42%. The business had revenue of $1.21 million during the quarter, compared to analysts’ expectations of $2.85 million. Sell-side analysts expect that VBI Vaccines will post -1.23 EPS for the current year.
About VBI Vaccines
VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.
Read More
- Five stocks we like better than VBI Vaccines
- Technology Stocks Explained: Here’s What to Know About Tech
- RXO Shares Surge Following New Acquisition Deal
- What is a buyback in stocks? A comprehensive guide for investors
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- How to Use the MarketBeat Stock Screener
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.